An observational study in Heart Valve Diseases, Heart Diseases and Cardiovascular Diseases, sponsored by Edwards Lifesciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Edwards Lifesciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Heart Valve Diseases by Edwards Lifesciences — 3 open to participants now, 7 under way, none of them phase 3. Heart Valve Diseases · Edwards Lifesciences.
Among the 21 studies in Heart Valve Diseases by Edwards Lifesciences, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 20th registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →3 of the 21 studies in Heart Valve Diseases by Edwards Lifesciences are open now, in 7 countries. Recruiting first, the newest first:
Edwards Lifesciences · Sites in Germany, Greece, Italy and 3 more countries
Edwards Lifesciences · Sites in United States
Ages 65+
By country, each count listing its studies:
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 75 is below the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Median enrollment 47 across the 18 interventional studies, 500 across the 3 observational. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
Edwards Lifesciences is the lead sponsor of 128 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 33 (94%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Heart Valve Diseases by Edwards Lifesciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.
Subjects in the TRIBLAZE study will be enrolled at up to 15 sites in the United States. The population will be participants requiring replacement of their native or prosthetic tricuspid valve.
The target population includes adult candidates who require replacement of their native or prosthetic tricuspid valve.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who were treated with the Edwards TRIFORMIS RESILIA heart valve
Device: Edwards TRIFORMIS RESILIA heart valve
Surgical replacement of the tricuspid valve with the Edwards TRIFORMIS RESILIA heart valve
Participant's average mean gradient measurement over time
Mean gradient is the average flow of blood through the tricuspid valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.
Time frame: 1 Year
Participant's average peak gradient measurement over time
Peak gradient is the maximum value measured of flow of blood through the tricuspid valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.
Time frame: 1 Year
Participant's average Effective Orifice Area (EOA) measurement over time
Effective orifice area represents the cross-sectional area of the blood flow downstream of the tricuspid valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve.
Time frame: 1 Year
Participant's amount of tricuspid valvular regurgitation measurement over time
Valvular regurgitation occurs when the valve in the heart does not close tightly, allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation, 1 = a trace of regurgitation, 2 = mild regurgitation, 3 = moderate regurgitation, and 4 represents severe regurgitation. Higher numbers on the scale show a worsening outcome.
Time frame: 1 Year
Participant's right ventricular function over time
Right ventricular function is the heart's ability to pump deoxygenated blood through the pulmonary circulation into the lungs. Right ventricular function is assessed via echocardiography. It is assessed on a scale of: Normal, Mild dysfunction, Moderate dysfunction, Moderate-severe dysfunction, or Severe dysfunction.
Time frame: 1 Year
Participant's amount of paravalvular leak over time
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.
Time frame: 1 Year
Participant's quality of life improvement as measured on the Kansas City Cardiomyopathy Questionnaire from baseline to 1 year
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a validated, disease-specific health status tool for patients with heart failure. It measures symptoms, physical and social limitations, and quality of life over the previous two weeks. Scores range from 0 to 100, where higher numbers indicate better health and fewer symptoms and lower numbers indicate wore health and more symptoms.
Time frame: Baseline and 1 Year
Participant's functional improvement over time from baseline for New York Heart Association (NYHA) Class
The New York Heart Association functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity. Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present even at rest.
Time frame: Baseline, 1 month, 1-, 2-, 3-, 4-, and 5- Years follow-up
Percentage of participant's freedom from all cause mortality
Participants' freedom from all cause mortality. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Percentage of participant's freedom from cardiovascular mortality
Participants' freedom from cardiovascular mortality. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Percentage of participant's freedom from valve-related mortality
Participants' freedom from valve-related mortality. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Percentage of participant's freedom from tricuspid valve reintervention
Participants' freedom from a reoperation on their tricuspid valve. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Percentage of participant's freedom from valve-related pulmonary embolism
Participants' freedom from valve-related pulmonary embolism. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Percentage of participant's freedom from valve-related valve thrombosis
Participants' freedom from valve-related valve thrombosis. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Percentage of participant's freedom from valve-related hemorrhage
Participants' freedom from valve-related hemorrhage. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Percentage of participant's freedom from valve-related endocarditis
Participants' freedom from valve-related endocarditis. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Percentage of participant's freedom from tricuspid valve-related heart failure hospitalization
Participants' freedom from tricuspid valve-related heart failure hospitalization. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Plan to share: No — Individual participant data will not be available to other researchers.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2030, 47 months after the start.
Of 116 observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 212. This study's planned 47 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.